Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-01-20
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the
laboratory may help doctors learn more about changes that may occur in DNA and identify
biomarkers related to cancer. It may also help doctors predict a patient's response to
treatment and help plan the best treatment.
PURPOSE: This phase II trial is studying gene expression in predicting treatment response in
patients receiving gemcitabine and S-1 for locally advanced unresectable or metastatic
pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Andrew Ko University of California, San Francisco
Collaborators:
Eli Lilly and Company National Cancer Institute (NCI) Taiho Pharmaceutical Co., Ltd.